John Kasperski - Pure Bioscience VP Sales
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
Insider
John Kasperski is VP Sales of Pure Bioscience
| Phone | 619 596 8600 |
| Web | https://www.purebio.com |
Pure Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.6231) % which means that it has lost $0.6231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2879) %, meaning that it created substantial loss on money invested by shareholders. Pure Bioscience's management efficiency ratios could be used to measure how well Pure Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Pure Bioscience currently holds 239 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Pure Bioscience has a current ratio of 1.98, which is within standard range for the sector. Debt can assist Pure Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Pure Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pure Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pure to invest in growth at high rates of return. When we think about Pure Bioscience's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Susan Kilsby | Unilever PLC ADR | 62 | |
| Peter Kulve | Unilever PLC ADR | 56 | |
| Stephan Habif | Colgate Palmolive | N/A | |
| Sanjiv Mehta | Unilever PLC ADR | 64 | |
| Mark Loomis | Estee Lauder Companies | N/A | |
| Dunia Shive | Kimberly Clark | 60 | |
| Troy Datcher | The Clorox | 52 | |
| Bruno Witvot | Unilever PLC ADR | 61 | |
| Deirdre Stanley | Estee Lauder Companies | 55 | |
| Diego Barral | The Clorox | 50 | |
| Herald Belton | Unilever PLC ADR | N/A | |
| Robert Long | Kimberly Clark | 67 | |
| Stanley III | Colgate Palmolive | 58 | |
| Jeffrey Baker | The Clorox | N/A | |
| Angela Hilt | The Clorox | 52 | |
| John Kooyman | Colgate Palmolive | 56 | |
| Nelson Urdaneta | Kimberly Clark | 52 | |
| S Maclin | Kimberly Clark | 64 | |
| Glenn Evans | Estee Lauder Companies | N/A | |
| C Harris | Colgate Palmolive | 64 | |
| Reginaldo Ecclissato | Unilever PLC ADR | 52 | |
Management Performance
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 |
Pure Bioscience Leadership Team
Elected by the shareholders, the Pure Bioscience's board of directors comprises two types of representatives: Pure Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pure. The board's role is to monitor Pure Bioscience's management team and ensure that shareholders' interests are well served. Pure Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pure Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tom CPA, Pres CEO | ||
| Thomas Myers, COO Director | ||
| John Kasperski, VP Sales | ||
| Zhinong Yan, Exec Devel | ||
| Mark Elliott, Principal Financial and Accounting Officer and VP of Fin. |
Pure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pure Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 111.36 M | ||||
| Shares Owned By Insiders | 41.23 % | ||||
| Number Of Shares Shorted | 222.97 K | ||||
| Price To Earning | 12.49 X | ||||
| Price To Book | 3.85 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |